Adicet Bio: dữ liệu topline của prula-cel cho SLE dự kiến công bố vào tháng 9 năm 2026

Last patient visit completed for the planned Phase 1 analysis of prula-cel in SLE with or without LN. Topline data from 22 patients (13 with ≥12 months follow-up) are now scheduled for release in September 2026. The company also notes FDA alignment on outpatient dosing and ongoing registrational trial design discussions.

Thông tin chính

Nộp lúc: 11:02 1 thg 9, 2026
Sự kiện: Kết quả topline
Chiều hướng: Trung lập
Công ty: ACETAdicet Bio
Tài sản: prulacabtagene leucel
Nguồn: SEC 8-K
Độ tin cậy: Có nguồn
bệnh nhân 12mo: 13
bệnh nhân được phân tích: 22

Trích đoạn nguồn

EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update Prula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeline targeting hematological malignancies and solid tumors; first candidate expected to enter clinical development in 2H 2027 REDWOOD CITY, Calif. – September 1, 2026 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell an

SEC 8-K